1. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. (January 2020) Authors: Lind, M.; Gettinger, S.; Borghaei, H.; Brahmer, J.; Chow, L.; Burgio, M.; De Castro Carpeno, J.; Pluzanski, A.; Arrieta, O.; Frontera, O. Aren; Chiari, R.; Butts, C.; Wojcik-Tomaszewska, J.; Coudert, B.; Garassino, M.; Ready, N.; Felip, E.; Garcia, M. Alonso; Waterhouse, D.; Domine, M. Journal: Lung cancer Issue: Volume 139(2020)Supplement 1 Page Start: S49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). (September 2015) Authors: Pietanza, M.C.; Spigel, D.; Bauer, T.M.; Ready, N.E.; Glisson, B.S.; Morgensztern, D.; Robert, F.; Salgia, R.; Kochendorfer, M.; Patel, M.; Strickland, D.K.; Govindan, R.; Burris, H.A.; Rudin, C.M.; Dylla, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S712 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗